BINIMETINIB
Total Payments
$546,145
Transactions
49
Doctors
16
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $65,592 | 5 | 0 |
| 2019 | $128,485 | 9 | 3 |
| 2018 | $137,222 | 20 | 10 |
| 2017 | $214,845 | 15 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $544,836 | 34 | 99.8% |
| Food and Beverage | $809.53 | 14 | 0.1% |
| Consulting Fee | $500.00 | 1 | 0.1% |
Payments by Type
Research
$544,836
34 transactions
General
$1,310
15 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I II MULTICENTER OPEN LABEL STUDY OF MAK683 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES | Novartis Pharmaceuticals Corporation | $436,422 | 0 |
| MODULAR PHASE II STUDY TO LINK TARGETED THERAPY TO PATIENTS WITH PATHWAY ACTIVATED TUMORS MODULE 3 MEK162 FOR PATIENTS WITH WITH RAS RAF MEK ACTIVATED TUMOR | Novartis Pharmaceuticals Corporation | $81,961 | 0 |
| A PHASE III RANDOMIZED 3 ARM OPEN LABEL MULTICENTER STUDY OF LGX818 PLUS MEK162 AND LGX818 MONOTHERAPY COMPARED WITH VEMURAFENIB IN PATIENTS WITH UNRESECTABLE OR METASTATIC BRAF V600 MUTANT MELANOMA | Novartis Pharmaceuticals Corporation | $16,795 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $6,283 | 5 |
| THE NEMO TRIAL NRAS MELANOMA AND MEK INHIBITOR A RANDOMIZED PHASE III OPEN LABEL MULTICENTER TWO ARM STUDY COMPARING THE EFFICACY OF MEK162 VERSUS DACARBAZINE IN PATIENTS WITH ADVANCED UNRESECTABLE OR METASTATIC NRAS MUTATION POSITIVE MELANOMA | Novartis Pharmaceuticals Corporation | $1,874 | 0 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO RECEIVED NO PRIOR HORMONAL THERAPY FOR ADVANCED DI | Novartis Pharmaceuticals Corporation | $1,500 | 0 |
Top Doctors Receiving Payments for BINIMETINIB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Fairfax, VA | $538,552 | 29 |
| , MD | Hematology & Oncology | Greenville, SC | $1,284 | 3 |
| , M.D | Internal Medicine | New York, NY | $1,257 | 1 |
| , MD | Medical Oncology | Boston, MA | $1,257 | 1 |
| , M.D, PHD | Internal Medicine | Houston, TX | $1,257 | 1 |
| , DO | Internal Medicine | Detroit, MI | $1,257 | 1 |
| , MD | Ophthalmology | Los Angeles, CA | $500.00 | 1 |
| , M.D | Anatomic Pathology | Dallas, TX | $160.84 | 3 |
| , M.D | Hematology & Oncology | Augusta, GA | $101.74 | 1 |
| , M.D | Hematology & Oncology | Omaha, NE | $100.00 | 1 |
| , M.D, PHD | Medical Oncology | Houston, TX | $96.00 | 1 |
| , MD | Surgery | Houston, TX | $96.00 | 1 |
| , MD | Internal Medicine | Houston, TX | $96.00 | 1 |
| , MD MBBS | Medical Oncology | Buffalo, NY | $45.06 | 1 |
| , MD | Surgery | Tampa, FL | $45.06 | 1 |
| , MD | Internal Medicine | Washington, DC | $29.14 | 1 |
| , D.O | Medical Oncology | Duarte, CA | $12.50 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $546,145
- Total Doctors 16
- Transactions 49
About BINIMETINIB
BINIMETINIB is a drug associated with $546,145 in payments to 16 healthcare providers, recorded across 49 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $65,592 was paid across 5 transactions to 0 doctors.
The most common payment nature for BINIMETINIB is "Unspecified" ($544,836, 99.8% of total).
BINIMETINIB is associated with 6 research studies, including "A PHASE I II MULTICENTER OPEN LABEL STUDY OF MAK683 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES" ($436,422).